@article{ae2b64ab8f264bad9bd9dd4ea2db5afa,
title = "Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features",
keywords = "B-cell acute lymphoblastic leukaemia (B-ALL), CRLF2-rearranged, NUTM1-rearranged, adult B-ALL, congenital B-ALL",
author = "McClure, \{Barbara J.\} and Manika Pal and Heatley, \{Susan L.\} and Jacqueline Rehn and Caitlin Schutz and James Breen and Venn, \{Nicola C.\} and Rosemary Sutton and Khaw, \{Seong Lin\} and Yeung, \{David T.\} and White, \{Deborah L.\}",
note = "Funding Information: DLW receives research support from BMS, and honoraria from BMS and AMGEN. DTY receives research support from BMS and Novartis, and honoraria from BMS, Novartis, Pfizer and AMGEN. SLK has received institutional research funding from AbbVie, Novartis, Jazz Pharmaceuticals, and Bristol‐Myers Squibb, and honoraria from Novartis, Jazz and Amgen. None of these agencies have had a role in the preparation of this manuscript. All other authors declare no conflicts of interest. Funding Information: The authors would like to acknowledge the contribution of the South Australian Genomics Centre (SAGC, SA, AUS) in the generation of data used in this publication. THE SAGC is supported by its founding partner institutes and by BioPlatforms Australia as part of the Australian Government{\textquoteright}s National Collaborative Research Infrastructure Strategy (NCRIS). The authors would also like to acknowledge the ACRF Cellular Imaging and Cytometry Core Facility (SAHMRI, Adelaide, SA, AUS) and the Genetics and Molecular Pathology at SA Pathology, Adelaide, SA, Australia. DLW is an NHMRC R.D. Wright II Fellow and a Beat Cancer Principal Research Fellow. DTY is an NHMRC Early Career Fellow. SLH is The Kids{\textquoteright} Cancer Project Fellow. SLK is supported by the Children{\textquoteright}s Cancer Foundation and the Department of Health and Human Services through the Victorian Cancer Agency (Project 134), Specialised Center of Research (SCOR) grant 7015‐18 from the Lymphoma and Leukemia Society and Vohra Family Foundation. This work was supported by funding from the National Health and Medical Research Council, Australia (NHRMC) (APP1057746); Cancer Australia PdCCR APP1128727; the Australian Genomics Health Alliance (AGHA); Beat Cancer; the Leukaemia Foundation and Bristol‐Meyers Squibb Company to DLW; Contributing Haematologist Committee (CHC) to DTY; and Australian Research Training Program (RTP) to JR. ",
year = "2022",
month = mar,
doi = "10.1111/bjh.17995",
language = "English",
volume = "196",
pages = "1407--1411",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "6",
}